Does Wegovy cause sneezing — and what does the evidence say?

What the STEP 1 trial and UK prescribing data actually recorded

The largest pivotal trial for Wegovy 2.4mg, the STEP 1 study published in the New England Journal of Medicine, enrolled over 1,900 adults with obesity and tracked adverse events carefully over 68 weeks. Sneezing did not feature among the reported side effects. The adverse events that did emerge consistently were gastrointestinal: nausea affected roughly four in ten participants, with diarrhoea, constipation and vomiting also documented, most commonly in the early weeks of treatment or following a dose increase.

The UK Summary of Product Characteristics, which is the authoritative clinical document governing how Wegovy is prescribed and used in Britain, lists no nasal or upper-respiratory symptoms as adverse reactions attributable to semaglutide. The NHS medicines page for semaglutide reflects the same picture. If sneezing were a pharmacologically plausible effect of GLP-1 receptor agonism, it would have appeared across the large STEP programme trials; the absence of that signal is itself informative.

This does not mean your sneezing is imaginary or unimportant. It means the likeliest explanation sits elsewhere, and finding that explanation matters more than attributing the symptom to the medicine by default.

Why people on Wegovy might sneeze more — and what actually explains it

Starting any new medicine treatment tends to make people more attuned to their body. A sneeze that would previously have gone unnoticed may now feel like a data point worth logging. That heightened awareness is entirely understandable, particularly in the first weeks of treatment.

More concretely, there are a few plausible non-drug explanations. Wegovy's most common side effects include nausea and changes to appetite, which occasionally prompt dietary shifts, and some foods, spices or strong aromas can trigger sneezing in sensitive individuals. Seasonal allergies are ubiquitous in the UK, anyone starting treatment in spring or autumn is sharing a timetable with pollen season. Viral upper-respiratory infections follow no calendar at all.

There is also a phenomenon called snatiation, where eating triggers sneezing in some people, thought to involve the vagus nerve. Because Wegovy at the 1mg stage of the dose escalation slows gastric emptying and alters how eating feels, changes to meal patterns or portion size might, theoretically, interact with this tendency. This is speculative rather than established, and it does not appear in semaglutide research, but it illustrates how the body's responses are rarely simple cause-and-effect chains.

If you are managing your Wegovy treatment and sneezing has arrived alongside other new symptoms, that combination is worth flagging to your prescriber promptly rather than waiting for your next scheduled review.

When a nasal symptom during Wegovy treatment does warrant urgent attention

Most sneezing on its own is trivial. Sneezing accompanied by certain other signs is not. Wegovy at the 2mg maintenance dose carries known serious adverse reactions including pancreatitis, gallbladder problems, allergic reactions and significant cardiovascular changes, which do not typically present as nasal symptoms, but an allergic reaction to semaglutide can include facial swelling, difficulty breathing or a rash alongside or instead of sneezing. That cluster needs same-day medical attention.

The MHRA's Yellow Card scheme exists precisely for situations like this: if you suspect that a medicine caused a symptom, including one that is not listed in the leaflet, you or your prescriber can submit a report. This is how post-market safety signals are built. It is a practical step, not an alarmist one, and it contributes to the evidence base for everyone using these treatments.

Symptoms that are severe, persistent or paired with anything unusual (swollen face, skin reaction, chest tightness, difficulty swallowing) are reasons to stop the injection and seek urgent care, not reasons to wait until Monday morning.

How to raise unexplained symptoms through a regulated prescribing service

If you are using Wegovy through a regulated online pharmacy and feel uncertain about a symptom, access to your prescriber should not feel like a barrier. At nume, aftercare is available seven days a week, and a real clinician reviews queries rather than a triage form that routes you to a leaflet.

The right question to ask is not "is this listed as a side effect" but "should I be concerned, and does this change anything about my treatment?" Your prescriber can answer that with your full medical picture in front of them, which no internet search can replicate. The FAQs on our site cover a range of common treatment questions, though for symptom concerns that persist, a direct conversation is always the better route.

For anyone still weighing up whether Wegovy suits them, or curious about how semaglutide compares to other licensed options, the weight-loss treatment overview explains what is currently available in the UK and how clinical assessment shapes the choice. Cost is a practical consideration too, and if you are just starting out on the 0.5mg introductory dose of Wegovy, the real cost of Wegovy in the UK page sets out what a private prescription actually covers and why headline prices vary as much as they do.

If you have unexplained symptoms during treatment, or if you are considering starting, a prescriber's assessment is the right next step. You can start your free consultation at any point, there is no referral needed and no waiting list.